−0.65USD
−52.15 MUSD
49.09 MUSD
34.48 M
About Biodesix, Inc.
Sector
Industry
CEO
Scott Hutton
Website
Headquarters
Boulder
Employees (FY)
217
Founded
2005
ISIN
US09075X1081
FIGI
BBG001J2LMV6
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Boulder, CO.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where BDSX is featured.
Frequently Asked Questions
The current price of BDSX is 1.21 USD — it has decreased by 3.20% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Biodesix, Inc. stocks are traded under the ticker BDSX.
Biodesix, Inc. is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
BDSX stock is 3.31% volatile and has beta coefficient of 0.18. Check out the list of the most volatile stocks — is Biodesix, Inc. there?
One year price forecast for Biodesix, Inc. has a max estimate of 3.50 USD and a min estimate of 3.50 USD.
BDSX earnings for the last quarter are −0.14 USD per share, whereas the estimation was −0.15 USD resulting in a 4.55% surprise. The estimated earnings for the next quarter are −0.11 USD per share. See more details about Biodesix, Inc. earnings.
Biodesix, Inc. revenue for the last quarter amounts to 13.49 M USD despite the estimated figure of 14.12 M USD. In the next quarter revenue is expected to reach 15.62 M USD.
Yes, you can track Biodesix, Inc. financials in yearly and quarterly reports right on TradingView.
BDSX stock has fallen by 3.20% compared to the previous week, the month change is a 11.68% fall, over the last year Biodesix, Inc. has showed a 35.98% decrease.
BDSX net income for the last quarter is −9.14 M USD, while the quarter before that showed −10.95 M USD of net income which accounts for 16.53% change. Track more Biodesix, Inc. financial stats to get the full picture.
Today Biodesix, Inc. has the market capitalization of 143.19 M, it has decreased by 5.37% over the last week.
No, BDSX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BDSX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Biodesix, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 217.00 employees. See our rating of the largest employees — is Biodesix, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Biodesix, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Biodesix, Inc. stock shows the sell signal. See more of Biodesix, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Biodesix, Inc. future price: according to them, BDSX price has a max estimate of 3.50 USD and a min estimate of 3.50 USD. Read a more detailed Biodesix, Inc. forecast: see what analysts think of Biodesix, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Biodesix, Inc. EBITDA is −36.55 M USD, and current EBITDA margin is −72.91%. See more stats in Biodesix, Inc. financial statements.